Treatment of patients with MYC rearrangement positive large B-cell lymphoma with R-CHOP plus lenalidomide: results of a multicenter phase II HOVON trial

Patients with MYC-rearrangement positive large B-cell lymphoma (MYC+ LBCL) have an inferior prognosis following standard first-line therapy with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP) compared to patients without MYC rearrangement. Although intensive chemoth...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Haematologica
Main Authors: Chamuleau, Martine E.D., Burggraaff, Coreline N., Nijland, Marcel, Bakunina, Katerina, Mous, Rogier, Lugtenburg, Pieternella J., Dierickx, Daan, van Imhoff, Gustaaf W., Vermaat, Joost S.P., A.F.Marijt, Eric, Visser, Otto, Mandigers, Caroline, Bilgin, Yavuz M., Beeker, Aart, Durian, Mark F., van Rees, Bas P., Bohmer, Lara H., Tick, Lidwine W., Boersma, Rinske S., Snijders, Tjeerd J.F., Schouten, Harry C., Koene, Harry R., de Jongh, Eva, Hijmering, Nathalie, Diepstra, Arjan, van de Berg, Anke, Arens, Anne I.J., Huijbregts, Julia, Hoekstra, Otto, Zijlstra, Josee M., de Jong, Daphne, Kersten, Marie José
Formato: Artigo
Idioma:Inglês
Publicado em: Fondazione Ferrata Storti 2019
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7716355/
https://ncbi.nlm.nih.gov/pubmed/33256379
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2019.238162
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados